Alaa R M Sayed

Alaa R M Sayed, Ph.D.

Research Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (407) 313-7067
Business Email: a.sayed@ufl.edu

About Alaa R M Sayed

Alaa Ropy Sayed, PhD, is a Research Assistant Professor in the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy. He completed his PhD degree in molecular biosciences at the Autonomous University of Madrid (UAM, Spain) in 2014. Then, he moved to Egypt and held a Faculty position at Fayoum University in 2015 until he joined University of Florida as a postdoctoral research associate in 2019.

Dr. Sayed’s current research is focused on studying the mechanisms of action of penicillins and related antibiotics from the β-lactam class. This includes in-depth studies on the receptor binding in lysed and intact bacteria, as well as the associated morphology changes using latest technologies. The latter include biochemical receptor binding studies, flow cytometry and automated confocal microscopy.

All β-lactam antibiotics target penicillin-binding proteins (PBPs) and a related class of targets, the so called L,D-transpeptidases (LDTs). Both of these enzymes are responsible for cell wall synthesis and maturation. Our team is applying latest proteomics via mass spectrometry for identifying these target enzymes in different bacteria. Dr. Sayed worked extensively on creating large databases for receptor binding data in lysed bacteria of Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa for about 50 β lactams and β-lactamase inhibitors.

Moreover, Dr. Sayed created and refined latest time-course assays on β-lactams for their receptor binding in intact bacteria of A. bau¬mannii, K. pneumoniae, and Mycobacterium tuberculosis. He has a publication on first penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus. He is also working on PBPs of mycobacterium tuberculosis and Mycobacterium avium complex. Finally, he developed a series of latest direct PBP-binding assays, which can quantify bound PBPs and LDTs using clickable probe β-lactams. This approach allows us to label bound and unbound PBPs using different fluorophores by employing azide or alkyne versions of the targeted β-lactams and BocillinTM FL for labeling of unbound PBPs.

Selection of major research grants where Dr. Sayed is playing a key role:

NIH/NIAID R01 AI136803 Bulitta JB (PI) Role: PI Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding

NIH/NIAID R01 AI148560 Tsuji BT (contact) / Bulitta JB Role: PI Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs

NIH/NIAID SBIR 2R44AI136213-04 Roemer T (PI) Role: Co-I Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci

NIH R01 R01 AI173064 Bulman Z (PI) Role: Co-I Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-3357-310X

Publications

2024
Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation.
Antimicrobial agents and chemotherapy. 68(3) [DOI] 10.1128/aac.01399-23. [PMID] 38329330.
2024
Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics.
Antimicrobial agents and chemotherapy. 68(2) [DOI] 10.1128/aac.01393-23. [PMID] 38169309.
2023
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology
Antimicrobial Agents and Chemotherapy. 67(6) [DOI] 10.1128/aac.01603-22. [PMID] 37199612.
2021
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Clinical pharmacology and therapeutics. 109(4):1000-1020 [DOI] 10.1002/cpt.2205. [PMID] 33576025.
2020
Biochemical and Molecular Characterization of Five Bacillus Isolates Displaying Remarkable Carboxymethyl Cellulase Activities
Current Microbiology. 77(10):3076-3084 [DOI] 10.1007/s00284-020-02135-8.
2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrobial agents and chemotherapy. 65(1) [DOI] 10.1128/AAC.01956-20. [PMID] 33106266.
2019
Effect of dietary sodium butyrate supplementation on growth, blood biochemistry, haematology and histomorphometry of intestine and immune organs of Japanese quail.
Animal : an international journal of animal bioscience. 13(6):1234-1244 [DOI] 10.1017/S1751731118002732. [PMID] 30333074.
2015
Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.
Antimicrobial agents and chemotherapy. 59(7):3925-34 [DOI] 10.1128/AAC.05150-14. [PMID] 25896695.

Grants

Dec 2023 – Jun 2024
Determination of receptor binding profiles and stability of novel drug candidates
Role: Principal Investigator
Funding: FEDORA PHARMACEUTICALS

Education

PhD, Molecular Biology
2014 · Universidad Autónoma de Madrid, Spain
MSc, Cellular and Molecular Biology
2011 · Universidad Autónoma de Madrid, Spain

Contact Details

Phones:
Business:
(407) 313-7067
Emails:
Business:
a.sayed@ufl.edu
Addresses:
Business Mailing:
6550 SANGER RD OFC 471
ORLANDO FL 32827
Business Street:
6550 SANGER RD OFC 471
GAINESVILLE FL 32611